# **Creating a New Protocol in BPMS**

# **Please Read This Notice**

Research with biological materials, such as recombinant DNA and/or biological pathogens, is required to be approved through an Institutional Biosafety Committee (IBC). A biosafety protocol is generated by a Principal Investigator to describe such research to provide the IBC with information to:

- 1. accurately assess risks associated with the research
- 2. recommend an appropriate biosafety level for conducting the research
- 3. approve the protocol to allow research to continue

Please be aware that all grants must be congruent with the biosafety protocol. If there is proposed work in a grant that is not in the biosafety protocol (but is required to be), the grant will be held.

## **Table of Contents**

1.	First steps	
2.	PI Entry	
3.	Home Screen	
4.	Check Protocol Status	
5.	File Cabinet	
6.	PI Information	
7.	Materials Used	
8.	Employees / Workers	
9.	Locations of Study	
10.	Project Description	
11.	PPE	
12.	Waste / Disinfectants	
13.	Accidental Exposure	
14.	Transportation	
15.	Dual Use	
16.	Risk Assessment	
17.	Addendums	
18.	Submit Protocol	

#### 1. To create a new registration:

- 1. In "My Protocols", click on "Create a new Protocol"
- Verify that a similar protocol does not already exist in the "Existing Protocols" panel
- 3. Click "no" if there is no similar existing protocols
- 4. Click on "Click to create a New Protocol" button

Protocols	Workers	Loca

#### My Protocols

Please select from the listing below to Create, View/Add Workers, Renew, Terminate or Amend a protocol with the Institutional Biosafety Committee. Please contact biosafety@rutgers.edu with any questions regarding this protocol registration system.

**Adding personnel** who will work with **Human Materials** (e.g., established human cell lines) will require that an Amendment be submitted as changes must also be made to Addendum E for the respective worker(s) added.

Make sure to click on the "Save Progress" button as you populate/edit each tab. Click on "Submit Protocol" to indicate the protocol is ready for pre-review (does not go out to entire committee). Protocols created by non-PIs will require PI Assurance to be submitted by PI.



### 2. Initial PI Information:

- 1. Fill out Principal Investigator Information
  - i. Information should be up-to-date
  - *ii.* Biosafety Level is the projected biosafety level of the laboratory for this protocol
- 2. Click "Save Button"

Protocols 🛛 🔻 Workers	Locations		
		Add Protocol	
PI Information	PI Information S	ection	
Employees/Workers	Pri	ncipal Investigator / Protocol Information	
Locations of Study	Principal Investigator	T	
РРЕ		ce you select a PI the four locked fields (grey color) I unlock and become editable	
Biomedical Waste	Protocol Title		
Disinfectants	Biosafety Level	<b>V</b>	1
Accidental Exposure	E-Mail Address		
Transportation	Department		=
Dual Use	Office Phone		
Risk Assessment	Emergency Phone (after hours) #		
Project Description	Save Button	2	
Materials Used	are button	2	

### 3. Home Screen:

- 1. "Save Progress" button allows progress to be saved. This should be clicked often to continually save your progress.
- 2. "Check Progress" button provides indications of sections yet to be completed
- 3. "Submit Protocol" button will submit protocol upon completion of ALL sections
- 4. Addendums Additional sections of the protocol to describe materials used. Each addendum will be created only after you complete the "Materials Used" section of the Protocol
- 5. File Cabinet allows uploads of additional documents (i.e. laboratory SOPs, plasmid/vector maps, permits, etc.)
- 6. Protocol Sections must be completed (see next pages of this guide)

Protocols Worke	Add Protocol Check Progress Locations Add Protocol Protocol Title: Protocol Examp Principal Investigator: Jessica McCorr Submit Protocol	
Intro	Introduction	S Add Comment
PI Information	Protocol Summary	
Materials Used	Authoree: Jessica McCormick-Ell	
Employees/Workers	Creator: Anthony Gresko	
	Department: IPO-Envir. Health & Safety	
ocations of Study	Title: UNIV BIOSAFETY OFFICER	
Project Description	Biosafety Level: BSL2	
PE	Protocol: Protocol Example Location(s):	
Vaste/Disinfectants	Endorsements:	
	Organisms:	
Accidental Exposure		
Fransportation	Materials U	Used
Dual Use		
Risk Assessment	k	
Questions	4	
	6	

#### 4. Check Protocol Status:

This section provides notifications of sections that are incomplete and must be completed prior to submission of protocol.

- 1. "Back to Protocol" allows return to home page of protocol
- 2. Clicking on the Bold Section Header will bring you to that section to edit/view it

tocols	Vorkers	Locations		
		(	Check Protocol Status	
	1		Back to Protocol	
	T -			
		Indicates that	at the section/addendum is complete.	
		😢 Indicates tha	at the section/addendum is NOT complete.	
		Application is N	NOT complete	
			ation is indicated below the section/addendum name	
		Click on the section/a	addendum name to goto the page.	
tocol Se	ctions			
and the second	nformation			<u> </u>
-		5 Government Agency(ie	es) and grant number(s)	_
• Yo	ou must provide the No	on-US Government Agen	ncy(ies) and grant number(s)	
• Yo	ou must provide the Ag	gency(ies) which have is	sed permits	
-	loyees/Workers	ervisor		
	ations of Study	st one Location		
🛛 PPE				
• Yo	ou must check at least	one box in the "PPE for	laboratory use" section	
• Y0	ou must answer Questi	on #1		
-	te/Disinfectants	one checkbox in the "Ou	uestion #1: Types" column OR provide a value ir	n the "Other" field
		_	uestion #1: How Treated/Disposed" column OR	
			uestion #2: Types" column OR provide a value in	
			uestion #2: How Treated/Disposed" column OR J	
			uestion #3: Types" column OR provide a value in	
		_	uestion #3: How Treated/Disposed" column OR J	
	ou must answer Questi		desition #3. now neared/bisposed column or	provide a value in the other field
	100 C		uestion #6: Equipment/Surfaces" column OR pro	ovide a value in the "Other" field
			uestion #6: Spills" column OR provide a value in	
		one checkbox in the Qu	action #0. Spins countin OK provide a value in	
_	dental Exposure ou must check the box	acknowledging that you	read the information about Accidental Exposure	es
_	nsportation ou must answer Questi	on #1		
o YC	ou must answer Questi	0n #1.		

- 🖸 Dual Use
  - You must check one of the options for "Dual Use"

### 5. File Cabinet:

This section allows uploads of additional documents (i.e. laboratory SOPs, plasmid/vector maps, permits, etc.)

- 1. Click "Choose File" to choose a file from computer
- 2. Once file displays next to "Choose File" button, click "Upload!" button
- 3. Click "Back to Protocol" to return to protocol
- 4. System files will show approval letters and PDFs once submitted/approved.

Protocols	Workers	Locations	Submissions	IACUC Protocols	REHS	-		
				Cabinet	— 3	}		
	1		Up oose File No file ch itted File Types: PI File Size: 5 Megaby		oload! -		— 2	
	Up	loaded Files				System Files		
							1	
						4		

### 6. PI Information Tab:

This section requires information surrounding funding sources and permits related to the research. Each question must be answered. If "yes" is answered, additional information is required to be input into the text box.

- 1. Question 3 requires PDF versions of permits to be uploaded to the File Cabinet tab.
- 2. Another reminder, it is good practice to click the "Save Progress" button as you complete each tab.

Protocols	Vorkers	Locations			
	2		Add Protocol		
		Prin	Protocol Title: Protocol Example (#19 cipal Investigator: Jessica McCormick-Ell		
📄 Sa	ave Progress 🖗 Che	eck Progress 🛛 🔒 Subn	nit Protocol	Addendums	ile Cabinet
Intro	PI I	nformation Section	1		<section-header> Add Comment</section-header>
PI Informatio	'n		Principal Investigator / Protocol Informa	ation	
Materials Use	d	Protocol Title Pro	ocol Example		
Employees/W	/orkers	Biosafety Level BS	2 •		
Locations of S	Study	PI Name Jes	sica McCormick-Ell	[Change	PI]
Project Descr		PI Title UNI	V BIOSAFETY OFFICER		
	puon	E-Mail Address jess	ica.mccormickell@rutgers.edu		
PPE		Department IPO	-Envir. Health & Safety		
Waste/Disinf	ectants	Office Phone 973	972 8424		
Accidental Ex	posure	Emergency Phone XXX	(-XXX-XXXX		
Transportatio	n	(encernote) a			
Dual Use			ing come from a US Government Agency?		
Risk Assessm	ent	Yes     No			
Questions		If "Yes", please	list all agencies along with grant numbers.		
Questions					
			ing come from a Non-US Government Agenc	y?	
		Yes     No			
			list all agencies along with grant numbers.		
			permits related to this research?		
		Yes     No			
			upload all permits to the file cabinet		
		Please list the a	gencies that have issued permits for this work.		

### 7. Materials Used:

Each question must be answered with either "Yes" or "No". Each time a "Yes" is checked, another Addendum tab (named A-1, A-2, A-3, B, C, etc.) is added in the Addendum section.

1. Once all questions in this section have been answered, Addendum tabs will be created in the Addendum section, which is described later in this guide.

otocols 🛛 🔻 Workers	Locatio	ons .	
		Add Protocol	
		Protocol Title: Protocol Example (#19-019) Principal Investigator: Jessica McCormick-Ell	
Save Progress	Check Progress	Submit Protocol Addendums	net
tro	Materials Use	ed	🖵 Add Co
Information T	o determine whi	nich Addendum(s) you may need to complete, please check "Yes" or "No" and comp	lete the as
A		ecessary. Select all the materials this project will use or produce.	fere the use
aterials Used			
anlovees /Workers		f primary human materials requires the selection of both "Human Subjects" as well a material", as Addendums C and E serve different purposes	as Human
anlovees /Workers		material", as Addendums C and E serve different purposes.	as Human
aployees/Workers H cations of Study		material", as Addendums C and E serve different purposes.	Addendum
nployees/Workers	Human Primate r Yes No	material", as Addendums C and E serve different purposes.	
nployees/Workers H cations of Study	Iuman Primate n Yes No	material", as Addendums C and E serve different purposes. Materials	Addendum
cations of Study oject Description	Iuman Primate r Yes No @ O R @ O C	material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems	Addendum A-1
aste/Disinfectants	Iuman Primate r	material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems Creation of Transgenic Animals	Addendum A-1 A-2
cations of Study oject Description PE aste/Disinfectants cidental Exposure	Yes No       Yes     No       Image: Im	material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems Creation of Transgenic Animals Use of Transgenic Plants	Addendum A-1 A-2 A-3
aste/Disinfectants	Yes No         Yes       No         Image: Second se	material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems Creation of Transgenic Animals Use of Transgenic Plants Use of Microorganisms (includes ALL strains of E. coli) Human subjects including the use of Embryonic Stem Cells: If the study is associated with an IRB	Addendum A-1 A-2 A-3 B
ansportation Laboration Laboratio	Yes No         Yes       No         Image: Second se	Material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems Creation of Transgenic Animals Use of Transgenic Plants Use of Microorganisms (includes ALL strains of E. coli) Human subjects including the use of Embryonic Stem Cells: If the study is associated with an IRB protocol, please complete this section. The use of Embryonic Stem Cells (including Somatic Cells [to be used for SCNT], Fetal	Addendum A-1 A-2 A-3 B C
pployees/Workers H cations of Study oject Description E aste/Disinfectants cidental Exposure ansportation al Use sk Assessment	Yes No         Yes       No         Image: Second se	material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems Creation of Transgenic Animals Use of Transgenic Plants Use of Microorganisms (includes ALL strains of E. coli) Human subjects including the use of Embryonic Stem Cells: If the study is associated with an IRB protocol, please complete this section. The use of Embryonic Stem Cells (including Somatic Cells [to be used for SCNT], Fetal Tissue/Cells, Embryos, Sperm, Oocytes)	Addendum A-1 A-2 A-3 B C C-1
pipoyees/Workers H cations of Study oject Description E este/Disinfectants cidental Exposure ansportation al Use	Yes No         Yes       No         Image: Second se	Material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems Creation of Transgenic Animals Use of Transgenic Plants Use of Microorganisms (includes ALL strains of E. coli) Human subjects including the use of Embryonic Stem Cells: If the study is associated with an IRB protocol, please complete this section. The use of Embryonic Stem Cells (including Somatic Cells [to be used for SCNT], Fetal Tissue/Cells, Embryos, Sperm, Oocytes) Administration of Biological/ Recombinant Materials to Animals Human/Non-Human Primate material including established human cell lines (Bloodborne	Addendum A-1 A-2 A-3 B C C-1 D
Hations of Study ations of Study ject Description ste/Disinfectants idental Exposure nsportation al Use k Assessment	Yes No         Yes       No         Image: Colspan="2">Image: Colspan="2"         Image: Colspan="2">Image: Colspan="2">Image: Colspan="2"         Image: Colspan="2"       Image: Colspan="2"         Image: Colsp	Material", as Addendums C and E serve different purposes. Materials Recombinant DNA, gene transfer and/or host vector systems Creation of Transgenic Animals Use of Transgenic Plants Use of Microorganisms (includes ALL strains of E. coli) Human subjects including the use of Embryonic Stem Cells: If the study is associated with an IRB protocol, please complete this section. The use of Embryonic Stem Cells (including Somatic Cells: If the study is associated with an IRB protocol, please complete this section. The use of Embryonic Stem Cells (including Somatic Cells [to be used for SCNT], Fetal Tissue/Cells, Embryos, Sperm, Oocytes) Administration of Biological/ Recombinant Materials to Animals Human/Non-Human Primate material including established human cell lines (Bloodborne Pathogens)	Addendum A-1 A-2 A-3 B C C-1 D E

Ι

Cell Sorting and/or Flow Cytometry

۲

### 8. Employees/Workers:

Follow the directions displayed to Add Workers to the protocol.

\*\* Adding new workers to an existing protocol can be done at this page and does NOT need to be submitted in an amendment.

- You must mark what role the worker has in the laboratory. Working with human cell lines (established cell lines) is working with Human materials
- Shipping/Transport should only be marked if someone is transporting materials on a road or by air (not hand carrying)



### 9. Locations of Study:

Add each room that workers will be utilizing for any work involved in this protocol, **including autoclave rooms**. Describe the function and containment controls utilized in each room.

Protocols 🛛 🔻 Worker	s Locations			
		Add Prot	ocol	
		Protocol Title: Proto Principal Investigator: Jessi	col Example (#19-019) ca McCormick-Ell	
Save Progress	🌼 Check Progress	Submit Protocol	@ Add	lendums File Cabinet
Intro	Locations of Study	1		Ӯ Add Comment
PI Information		ich are used with this protoc	ol. Make sure to include V	ivarium Procedure
Materials Used	Rooms, as applicable.			
Employees/Workers	If a location is not pres	ent, then click the "Add Loc	ation" button to add it to th	ne table below.
Locations of Study			Saved Locations	
Project Description				
PPE	Add Location			
Waste/Disinfectants				
Accidental Exposure				
Transportation				
Dual Use				
Risk Assessment				
Questions				

### **10. Project Description:**

- 1. Please describe your research in terms that a lay person can understand. Do NOT copy and paste from a grant what the specific aims are.
- 2. This question asks to describe experiments that you will be performing and why specific biological material is needed for those experiments. For each experiment, describe what precautions will be used to minimize risk (engineering controls, work practices, etc.). This is NOT a recreation of your grant but instead is a section to describe how you will perform each of your experiments safely. Please include work with animals, human subjects, and analysis of infected tissues.

SEE NEXT PAGE FOR VERY HELPFUL HINTS

Protocols 🛛 🔻 Workers	Locations		
	Add Pi	rotocol	
	Protocol Title: <b>Pr</b> Principal Investigator: <b>Je</b>	rotocol Example (#19-019) essica McCormick-Ell	
Save Progress	Check Progress	Addendums File Cabinet	
Intro	Project Description	👤 Add Comment	
		made up of a diverse group of people. It is therefore important to use	
Materials Used	with non-scientific backgrounds. Please provide	ific evaluation as well as general enough to be understood by people e sufficient information for Committee members to evaluate the work	
	for purposes of making a biohazard risk assessm accepted	nent. Project descriptions taken from grant applications will not be	
Locations of Study	1. In lay language, describe your research object	tives and hypotheses	
Project Description	1. In my minguage, describe your research object		
PPE			
Waste/Disinfectants			1
Accidental Exposure			
Transportation			
Dual Use			
Risk Assessment		r research methodology. Be sure to explain how and inection between this IBC protocol, IRB, ESCRO and/	
Questions	or IACUC be sure to describe the links.		
			2

### **10. Project Description**

**HELPFUL HINT 1**: This section is NOT a copy/paste from the specific aims section of a grant. If the grant is selling how impactful the research will be, the project description is selling how safe the research will be.

- **Grant Example**: "Performing our vaccine challenge into mice will determine the efficacy of the vaccine in inducing both cellular and humoral immunity against infection which will determine possibility of a platform to prevent human disease"
- **Project Description Example**: "Performing our vaccine challenge into mice will be done inside a Class II biosafety cabinet to protect against potential aerosols. Injection will be performed with safe sharps to reduce the chance of needle stick exposure.

This is going to a Biosafety Officer and IBC reviewer, not a funding committee. They are not checking for the validity and/or reasoning for doing your science, but instead are reviewing for the safety of your science.

**HELPFUL HINT 2:** The **Project Description** section should describe how each experiment is done TO A CERTAIN EXTENT. This means that each experiment should be described as to what they are doing and how, but specific SOPs are not to be written here. Example below.

**Good**: Cells will be transfected with RNAi molecules against XYZ gene and are then infected with example virus. Cell monolayer is harvested for total nucleic acid or protein purification to determine gene expression using SOP 1(uploaded to file cabinet)

**Bad**: 1. Open flask. 2. Remove media. 3. Wash with PBS. 4. Transfect cells with 50 nanograms/1 million cells of siRNA targeting XYZ gene. (And continuing like this)

The bad example above is in SOP format. SOPs can be mentioned but should not be written out in the **Project Description**. They should be uploaded into the **File Cabinet**, which is a section to store all external files (SOPs, plasmid maps, permits, publications showing data).

### 11. PPE:

Check all boxes that would apply to PPE that would be required to work with the biological hazards in your laboratory.

Protocols 🛛 🗸 Workers	5 Locations			
		Add Protocol		
	Princ	Protocol Title: Protocol Exa pal Investigator: Jessica McC		
Save Progress	🌼 Check Progress	t Protocol	Addendum	s 📴 File Cabinet
Intro	Personal Protective Equ	ipment		🖓 Add Comment
PI Information	Check all the applies while ha	anding biological agents:		
Materials Used	PPE for labor	atory use	PPE for use with h	uman patients or animals
Employees/Workers	Eye Protection	isposable Gloves	Eye Protection	<ul> <li>Disposable Gloves</li> </ul>
Locations of Study	Shoe Covers	ull Face Shield	Shoe Covers	Full Face Shield
Project Description		air Covers	Lab Coat	Hair Covers
РРЕ		-95 Respirator owered Air Purifying Respirator	<ul> <li>Surgical Mask</li> <li>N-100 Respirator</li> </ul>	N-95 Respirator     Powered Air Purifying Respirator
Waste/Disinfectants	Tyvek Coverall	prons with sleeves	Tyvek Coverall	Aprons with sleeves
Accidental Exposure	Aprons without sleeves	over sleeves	Aprons without sleeves	Cover sleeves
Transportation	OtherRespirators require fit te	sting	Other	fit testing
Dual Use	Respirators require in te	sting	Respirators require	
Risk Assessment	_	n patients or animals be require	ed?	
Questions	Yes     No			

#### 12. Waste/Disinfectants:

Describe how all types of waste will be treated. If you need more information, please refer to the RU bioguide for more information (see link below). <u>https://ipo.rutgers.edu/sites/default/files/RU%20Biosafety%20Guide.pdf</u>

- 70% ethanol is never acceptable as a primary disinfectant

ocols 🔻 Workers	Locations	
	,	Add Protocol
		l Title: Protocol Example (#19-019) gator: Jessica McCormick-Ell
E Save Progress	Check Progress Submit Protocol	Addendums File Cabinet
w	aste / Disinfectants	😞 Add Comm
		s of Regulated Medical Waste (RMW) generated by this protocol and how i
		ur laboratory. Please refer to the RU Policy for the Disposal of Biological <u>biowaste_policy_10-07-13e.pdf</u> , if necessary.
yees/Workers		
ons of Study	. My laboratory will produce the follow	wing types of "Solids (non-glass)" biomedical waste (check appropriate boxes)
t Description	Types	How Treated/Disposed
	Culture plates/dishes Flasks	Chemical treatment with 10% bleach - dispose in RMW box
	Serological pipettes	Autoclave - dispose in RMW box
/Disinfectants	Pipette tips	Collect untreated directly into RMW box (BSL-1 waste only)
ntal Exposure	Falcon tubes	Autoclave in <u>clear autoclave bag</u> - dispose in dumpster (Permitted in non- RBHS laboratories that conduct only BSL-1 work)
ortation	Microfuge tubes	
lse		
ssessment	Other:	
ions	other:	
2.	My laboratory will produce the follo	owing types of "Liquids" biomedical waste (check appropriate boxes)
	Types	How Treated/Disposed
	Waste from disinfection traps	Chemical treatment with 10% bleach - dispose down drain
	Effluent from processing	Autoclave - dispose down drain
	None Generated	Collect in leak-proof container and place in RMW box
	Other:	

### 13. Accidental Exposure:

Read and acknowledge this disclaimer.

Protoc	ols	<b>~</b> W	Vorkers	1	Locations														
								Add	Proto	col									
						Prin	Protoco cipal Invest		Protoc Jessica		• •		19)						
	🔚 Sav	e Progr	ress	🔅 Check Pr	rogress	🛃 Subn	nit Protocol						🖉 Adde	ndums		File (	Cabinet		
Intro				Accidental Exposure					🖓 Add Comment					nment					
PI Info	rmation			In case of a															
Materials Used				contact Rutgers Occupational Health (New Brunswick), Robert Wood Johnson Employee Health (New Brunswick/Piscataway), or New Jersey Medical School Occupational Medicine (Newark) as soon as possible for consultation and/or treatment at a Rutgers designated healthcare facility. I must complete an Accident Report on http://myrehs.rutgers.edu on the day of the															
Employees/Workers				incident. Th									on <u>nup.</u>	//111916	:115.1 U	Lyers.e	<u>au</u> on t	ne uay u	i the
Locations of Study			<ul> <li>Rutgers employees: Occupational Health - 848-932-8254</li> <li>RBHS (legacy UMDNJ) employees in New Brunswick/Piscataway: RWJMS Employee Health - 848-445-0123</li> </ul>																
Project	Project Description PPE			<ul> <li>RBHS (legacy UMDNJ) employees in Newark: NJMS Occupational Medicine Service - 973-972-2900</li> <li>Compliance with the NIH Guidelines for Recombinant DNA requires that Rutgers University, as a recipient of NIH funds, "reports any significant problems, violations of the NIH Guidelines or any significant research-related accidents or illnesses (Sections IV-B-1-i, -2-b-(7), -3-c-(2), -7-a-(3)). Compliance with the New Jersey Public Employee Occupational Safety and</li> </ul>															
PPE																			
Waste/Disinfectants Accidental Exposure Transportation			Health Act's General Duty Clause that requires that Rutgers provide "a place of employment which [is] free from recognized hazards that are causing or are likely to cause death or serious physical harm to [its] employees" (Sec. 5 Duties).																
			Reportable Incident: Any accident that leads to personal injury or illness. Any breach of containment. Any violation of the NIH Guidelines. Examples of reportable incidents include, but are not limited to, spills of recombinant materials outside of the biosafety cabinet, needlesticks, animal bites from infected animals, unprotected skin exposures to biological agents, and the																
Dual U	se			escape or in with a micr						n. Appea	arance	of syn	nptoms	indicat	ive of	labora	atory ac	quired ill	ness
Risk As	ssessmei	nt		My staff h															
Questions				EXPOSURE TO INFECTIOUS AGENTS or RDNA, CUTS or PUNCTURES, ASPIRATION OF AEROSOLIZED MATERIAL, ETC.) SHALL BE REPORTED via the On-line Accident and Incident Reporting System available at MyREHS website or <u>https://myrehs.rutgers.edu</u> .															

By checking this box, I acknowledge that the above statement is true and I confirm that all persons involved with this protocol will comply with all applicable laws, rules, and regulations.

### 14. Transportation:

Describe how you will be transporting biological material. .

Protocols	Vorkers	Locations			
			Add Protocol		
		F	Protocol Title: Protocol Example (# Principal Investigator: Jessica McCormick-		
Sav	e Progress	Check Progress	ubmit Protocol	🖉 Addendums 🛛 🖨 F	ile Cabinet
Intro	•	Transportation/Shi	oping (includes 'hand-carrying' sp	ecimens)	🖓 Add Comment
PI Information	I	f you are involved in shi	pping hazardous materials and/or dangero	us goods, please read the	nformation provided at:
Materials Used			nv_dot.html. Materials being hand-carried urrounded by absorbent material. Ensure t		
Employees/Wo		vent of an accidental rel		5 1	
Locations of St	udy		ansported outside of the laboratory in which	they are being used?	
Project Descrip	tion	<ul> <li>Yes</li> <li>No</li> </ul>			
PPE					]
Waste/Disinfed		<ol> <li>Will materials be ca • Yes     </li> </ol>	rried by hand?		
Accidental Expo	osure	O No			
Transportation		If "Yes", please desc of the shipment.	ibe the hand transport procedures. Be sure to inc	ude the origin and destination	
Dual Use					
Risk Assessmer	nt			/	
Questions					]
			ansported by vehicle?		
		<ul><li>Yes</li><li>No</li></ul>			
	Γ	4. Will materials be st	ipped to another university/ entity?		1°

### 15. Dual Use:

**Risk Assessment** 

Questions

Check any box that may apply to your research. If none apply, check "None of the above apply". Please contact Biosafety if you need help determining whether research could be Dual Use.

Protocols 🛛 🔻 Workers	Locations	
	Add Protocol	
	Protocol Title: Protocol Example (#19-019) Principal Investigator: Jessica McCormick-Ell	
Save Progress	Deck Progress Submit Protocol Addendums	5 File Cabinet
Intro	Dual Use Research	🔜 Add Comment
PI Information	Check any categories below the apply to your project	
Materials Used	Renders a useful vaccine ineffective	
Employees/Workers	Enhances pathogen virulence	
Locations of Study	<ul> <li>Widens a pathogen's host range</li> <li>Weaponization (e.g. environmental stabilization of pathogens)</li> </ul>	
Project Description	Add antibiotic resistance affecting response to a clinically useful drug	
PPE	Increases pathogen transmissibility	
Waste/Disinfectants	Lets a pathogen evade diagnostic or detection modalities	
Accidental Exposure	Generating a novel pathogenic agent or toxin, or reconstitute en eradicated biological agent	
Transportation	None of the above apply	
Dual Use		

### 16. Risk Assessment:

Please describe in detail the hazards associated with the biological materials you will be working with.

- Please do not write "no risk" when working with human cells. Human cell lines always have a risk of blood borne pathogens (even established cell lines).
- Acknowledge the risk of gene expression in a lab worker that would be accidentally exposed to recombinant/gene editing technologies (viral vectors, CRISPR, etc)
- If you are working with Sharps, as would be mentioned in the Waste section, please describe the risks associated with Sharps in this section as well.

Protocols	Vorkers	Locations	i.		
			Add Protocol		
			col Title: Protocol Exar estigator: Jessica McCo		
E Save	e Progress	Check Progress	bl	Addendums	File Cabinet
Intro	R	isk Assessment			🖓 Add Comment
PI Information	0		inistration of rDNA/synt	netic nucleic acid molecule	s to
Materials Used		human subjects?  Ves (You will only have to answe	r Questions 8 through 21)		
Employees/Wor	rkers	No (You will only have to answer		20 and 21)	
Locations of Stu		). Will work in protocol involve the	use of sharps?		
Project Descript	tion	O Yes			
РРЕ		No			
Waste/Disinfect	tants 2	<ol> <li>Identify and describe the risk(s) used in the experiment and meth</li> </ol>			
Accidental Expo	sure	or the environment. a. 1. Increased risk of exposure		•	
Transportation		aerosols from centrifugation, syringes), cage cleaning of in should be addressed in this s	sonication, homogenization fected animals, animal surg	, use of sharps (needles, glas.	s, or
Dual Use		b. 2. Identify known/suspected		osure for each agent involved,	, as
Risk Assessment	it	applicable.			
Questions					
	I	I			I

### 17. Addendums:

- 1. Follow the directions and answer each Yes/No question by clicking on either "Yes" or "No".
- Once all questions for Addendum A have been answered, proceed to Addendum "A-1" by clicking on the red tab to the left of the screen entitled "Addendum A-1". Complete ALL Addendums that are present. Keep in mind, you only have Addendum tabs to which you checked "yes" to in the "Materials Used" tab from the Protocol.
- 3. For a sample response to these questions, please see the attached document "Biosafety Protocol Template"

Protocols 🛛 💙 Wo	orkers Locations									
	Addendums									
Save Progres	is Check Progress	Protocol Pile Cabinet								
Addendum A	Addendum A	🖓 Add Comme								
Addendum A-1	Recombinant and Synthetic Nucleic Acids Questionnaire									
Addendum A-2	Please answer each by clicking on the "Yes" or "No" button next	to the question.								
Addendum A-3		<ul> <li>The button will turn an orange color to indicate your answer.</li> <li>If your click on the question more information about that question will appear (the question will be red and italicized).</li> </ul>								
Addendum B	once you place the mouse cursor over the question).									
Addendum C	<ul> <li>Answering "Yes" to certain questions will cause more questions to appear which must be answered.</li> <li>If all the Non-Exemption questions are answered "No", then the Exemption questions (scroll down to view the tan- colored boxes) must also be answered.</li> </ul>									
Addendum C-1	ddendum C-1									
Addendum D Addendum D Addendum D										
Addendum E	acquire it normally, which could con	drug resistance trait to an organism that does not npromise the use of the drug to control the disease agriculture? Note: this does not refer to resistance								
Addendum F	used for selectable markers.									
Addendum G	Yes No. #2) Does the recombinant or synthetic	nucleic acids contain genes coding for molecules								
Addendum H	Yes No #2) Does the recombinant or synthetic toxic to vertebrates (LD50 <100 nanograms / kg body v	n de la constante de la constan								
Addendum I	(LDS0 < 100 hanograms / kg body (	wtjr								
	Yes No #3) Is the proposed experiment is equivapproved by the NIH Director as a f	valent to an experiment that has previously been Major Action?								
Addendum C-1 is The use of Embryonic Stem Cells (including Somati Cells [to be used for		on of recombinant or synthetic nucleic acid molecules								
SCNT], Fetal	V #5) Are any human or animal nathogen									

17. Addendum A and A-1 Helpful Hints:

Addendums A and A-1 are often a source of difficulty when creating a protocol. Here are some hints to think about when/if you are required to complete these addendums. Also, the IBC Protocol Example is a great resource to show you an example of responses to the questions in these addendums.

### Addendum A

This section is to determine how rDNA will be used.

- 1. Where does the research fall under the NIH guidelines?
- 2. What/how rDNA is being used?
- 3. What/how viral vectors are being used?
- 4. Do genes of interest (rDNA) pose an increased risk? (oncogenic, immunosuppressive)
- 5. What are the viral vector concerns?
  - a) Competent vs Incompetent
  - b) Recombination potential
  - c) Residual viral gene expression
  - d) Method of vector construction/propagation
  - e) Integration potential

If the research includes CRISPR or viral vectors, make sure you read/sign the CRISPR guidesheet or viral vector factsheets and upload to the **File Cabinet**.

### Addendum A-1

This section is to further determine the risk of rDNA and vectors.

- 1. Do the vectors/strains/gene targets present any hazards?
  - a) Are the gene targets oncogenic?
  - b) Does putting the vector into the host present additional risks?
- 2. Is the viral vector contaminated with replication competent virus?

*E.coli* must be mentioned here. You also need to ensure all plasmids are listed, including the transfer **AND** packaging plasmids. Plasmid maps should be uploaded into the **File Cabinet**, and should relate to the vectors in the chart here.

### 18. Submit Protocol:

- 1. Click on the "Submit Protocol" button to submit a finished protocol.
- 2. When the protocol is being reviewed by Biosafety, the PI will need to answer questions in the questions tab. When reviewers ask for more information through a question, please provide the information **in the requested sections of the protocol.**

